Literature DB >> 317844

Brain distribution and kinetics of 11C-chlorpromazine in schizophrenics: positron emission tomography studies.

D Comar, E Zarifian, M Verhas, F Soussaline, M Maziere, G Berger, H Loo, H Cuche, C Kellershohn, P Deniker.   

Abstract

The positron emitter 11C (20 minutes half-life) permits the labeling of chlorpromazine (CPZ) and the study of its distribution in humans by external counting. Trace amounts of 11C-CPZ were injected intravenously into 22 schizophrenic patients all untreated for several months with neuroleptics. The brain uptake was 6.04 +/- 1.6% of the injected dose 15 minutes after the injection, and it remained constant for 45 minutes. By positron emission tomography, the drug distribution was shown to be in the gray matter, and such structures as the cortex, caudate nucleus, thalamus and putamen could be identified. This new methodology will be helpful in studying specific receptors in humans in a noninvasive way.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 317844     DOI: 10.1016/0165-1781(79)90024-6

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  7 in total

1.  18F-fallypride binding potential in patients with schizophrenia compared to healthy controls.

Authors:  Douglas S Lehrer; Bradley T Christian; Cemil Kirbas; Meicheng Chiang; Shawn Sidhu; Holly Short; Binquan Wang; Bingzhi Shi; King-Wai Chu; Brian Merrill; Monte S Buchsbaum
Journal:  Schizophr Res       Date:  2010-07-23       Impact factor: 4.939

Review 2.  Where have we got to with neuroreceptor mapping of the human brain?

Authors:  B Mazière; M Mazière
Journal:  Eur J Nucl Med       Date:  1990

3.  Chlorpromazine, a Clinically Approved Drug, Inhibits SARS-CoV-2 Nucleocapsid-Mediated Induction of IL-6 in Human Monocytes.

Authors:  Iwona Karwaciak; Kaja Karaś; Anna Sałkowska; Joanna Pastwińska; Marcin Ratajewski
Journal:  Molecules       Date:  2022-06-07       Impact factor: 4.927

4.  Estimating the effect of endogenous dopamine on baseline [(11) C]-(+)-PHNO binding in the human brain.

Authors:  Fernando Caravaggio; Lawrence S Kegeles; Alan A Wilson; Gary Remington; Carol Borlido; David C Mamo; Ariel Graff-Guerrero
Journal:  Synapse       Date:  2016-07-11       Impact factor: 2.562

5.  Repurposing chlorpromazine to treat COVID-19: The reCoVery study.

Authors:  M Plaze; D Attali; A-C Petit; M Blatzer; E Simon-Loriere; F Vinckier; A Cachia; F Chrétien; R Gaillard
Journal:  Encephale       Date:  2020-05-16       Impact factor: 1.291

6.  [Repurposing of chlorpromazine in COVID-19 treatment: the reCoVery study].

Authors:  M Plaze; D Attali; A-C Petit; M Blatzer; E Simon-Loriere; F Vinckier; A Cachia; F Chrétien; R Gaillard
Journal:  Encephale       Date:  2020-04-29       Impact factor: 1.291

7.  Inhibition of the replication of SARS-CoV-2 in human cells by the FDA-approved drug chlorpromazine.

Authors:  Marion Plaze; David Attali; Matthieu Prot; Anne-Cécile Petit; Michael Blatzer; Fabien Vinckier; Laurine Levillayer; Jeanne Chiaravalli; Florent Perin-Dureau; Arnaud Cachia; Gérard Friedlander; Fabrice Chrétien; Etienne Simon-Loriere; Raphaël Gaillard
Journal:  Int J Antimicrob Agents       Date:  2020-12-30       Impact factor: 5.283

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.